Individual Treatment Of Advanced Non-small Cell Lung Cancer

Incidence and mortality rates of lung cancer has taken the first position amongcancers leading to death and increased stable in our country.[1]The only reason is lack ofcontrolling pathogenic factors, lack of early diagnosis, and lack of proper treatment.[2]Individual treatment has not been popularized, while traditional standardized treatment isbased on the same physical signs.[3]The third generation chemotherapy of platinum drugsand molecular targeted agents are not effective for everyone. Recent researches haverevealed that the therapeutic effects of anti-tumor drugs are related to some genes. So therelationship between gene and drugs is important for research to adjust the drug schemeand dose to achieve individual treatment. This paper aims to find if the detection of relationbetween them could help improve the therapeutic effect.ObjectTo detect the expression of ERCC1、TUBB3、TYMS、RRM1mRNA, and genicmutation of EGFR in patients with advanced non-small cell lung cancer with the method ofgene target detection, and find the best drug scheme and dose in clinical experiences.MethodsForty-two cases of advanced non-small cell lung cancer received gene target detectionas the experiment group. The liquid phase chip technique was used to detect the expressionof ERCC1、TUBB3、TYMS、RRM1mRNA. Mutation enriched liquid chip technology wasused to detect the genic mutation of EGFR. The results were taken as the guidance for thedrug use. Another40cases received traditional standardized TP treatment as control group,all patients received at least4treatment cycles,3months each cycle, and receivedassessment every2cycles. The survival rates in2groups were compared with X2test, andSPSS3.0software.Results The liquid phase chip technique revealed low expression of ERCC1mRNA in18cases, expression in15cases, high expression in9cases; low expression of RRM1mRNAin13cases, expression in18cases, high expression in11cases; low expression of TUBB3mRNA in11cases, expression in20cases, high expression in8cases; low expression ofTYMSmRNA in9cases, expression in19cases, high expression in14cases.The liquid phase chip technique revealed12cases of EGFR gene mutation.It is suggested that18cases were sensitive to platimum drug,13cases were sensitiveto gemcitabine,11cases were sensitive to taxane,9cases were sensitive to pemetrexed,and it is suggested that12cases could receive EGFR-TKI treatment.All patients were able to endure therapy. The experimental group, the survival ratewas significantly higher(71.43%vs45%，61.9%vs20%), with significant difference (P<0.05).KPS score has increased from63.56±17.34preoperatively to85.24±19.23postoperatively, with significant difference (P<0.05).ConclusionThe liquid phase chip technique has advantages of high sensitivity, high specificity. Itcould be used for detecting tumor related gene, guiding drug use, avoiding useless druguse.